Cure for immune-tolerant hepatitis B in children: Is it an achievable target with sequential combo therapy with lamivudine and interferon?

Journal of Viral Hepatitis

Volumn 20, Issue 5, 2013, Pages 311-316

  Poddar, Ujjal ^a   Yachha, S K ^a   Agarwal, J ^a   Krishnani, N ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

chronic hepatitis B; HBsAg clearance; perinatal

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ARTICLE; CASE CONTROL STUDY; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84876128013     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12007     Document Type: Article

References (27)

1. Poddar U, Thapa BR, Rao KLN, Sing K,. Etiological spectrum of esophageal varices due to portal hypertension in Indian children: is it different from the West? J Gastroenterol Hepatol 2008; 23: 1354-1357.
2. Arora NK, Arora S, Ahuja A, et al,. Alpha 1 antitrypsin deficiency in children with chronic liver disease in north India. Indian Pediatr 2010; 47: 1015-1023.
3. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107. (Pubitemid 38365759)
4. Chu CM, Liaw YF,. Natural history differences in perinatally versus adult-acquired disease. Curr Hepat Rep 2004; 3: 123-131.
5. Chu CM, Karayiannis P, Fowler MJF, Monjardino J, Liaw YF, Thomas HC,. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985; 5: 431-434. (Pubitemid 15065950)
6. Liaw YF,. Hepatic flares and hepatitis B e antigen seroconversion: implication in anti hepatitis B virus therapy. J Gastroenterol Hepatol 2003; 18: 246-252.
7. Chen CH, Chen YY, Chen GH, et al,. Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol 2004; 40: 653-659. (Pubitemid 38367788)
8. D'Antiga L, Marion AW, Atkins M, Moorat A, Vergani D, Mieli-Vergani G,. Combined lamivudine/interferon-alfa treatment in immunetolerant children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006; 148: 228-233.
9. Lai CL, Lin HJ, Lau JN, et al,. Effect of recombinant alfa 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991; 78: 155-163.
10. Jara P, Bortolotti F,. Interferon alfa treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999; 29: 163-170. (Pubitemid 30366166)
11. Jonas MM, Kelly DA, Mizerski J, et al,. Clinical trial of lamvudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-1713. (Pubitemid 34547484)
12. Boni C, Bertoletti A, Penna A, et al,. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975. (Pubitemid 28419565)
13. Chisari FV, Ferrari C,. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
14. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP,. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170: 1418-1423. (Pubitemid 24369900)
15. Boni C, Penna A, Graham SO, et al,. Lamivudine can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-971. (Pubitemid 32246646)
16. Knodell RG, Ishak KG, Black WC, et al,. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435. (Pubitemid 12218164)
17. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Haussinger D,. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-1013. (Pubitemid 40873918)
18. Wai CT, Chu C-J, Hussainn M, Lok AS,. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430. (Pubitemid 35403533)
19. Oldstone MBA,. Molecular anatomy of viral persistence. J Virol 1991; 65: 6381-6383.
20. Carey I, D'Antiga L, Bansal S, et al,. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus infected children on combination therapy. J Virol 2011; 85: 2416-2428.
21. Lok AS, Zoulim F, Locarnini S, et al,. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-265. (Pubitemid 47171942)
22. Tatulli I, Francavilla R, Rizzo GL, et al,. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001; 35: 805-810. (Pubitemid 34717673)
23. Arase Y, Ikeda K, Suzuki F, et al,. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119: 71e9-71e16.
24. Yuen MF, Wong DK, Fung J, et al,. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-1199.
25. Wursthorn K, Lutgehetmann M, Dandri M, et al,. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684. (Pubitemid 44433724)
26. Chan HL, Wong VW, Tse AM, et al,. Serum hepatitis B surface antigen quantification can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468. (Pubitemid 350181604)
27. Keeffe EB, Dieterich DT, Han SB, et al,. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States; an update. Clin Gastroenterol Hepatol 2006; 4: 936-962. (Pubitemid 44118844)